To the Editor The study by Cercek et al1 in JAMA Oncology was inspiring. It detailed a phase 2 single-arm study to evaluate and validate the efficacy and safety of combining hepatic arterial infusion (HAI) of floxuridine (14-day infusion, 4-week cycle) with systemic gemcitabine and oxaliplatin in patients (N = 38) with unresectable intrahepatic cholangiocarcinoma (IHC). The median progression-free survival (PFS) was 11.8 months (1-sided 90% CI, 11.1), and the overall survival (OS) was 25.0 months (95% CI, 20.6-not reached).1 Herein, we present several concerns about the study outcomes.